Skip to main content

Confronting Knowledge Gaps in Rare Hematologic Malignancies

In the beginning of 2022, i3 Health and Oncology Data Advisor hosted ODACon: A Rare Hematologic Malignancies Symposium, a live, virtual symposium which provided five educational activities that challenged knowledge gaps experienced by clinicians regarding hematologic malignancies, including acute lymphoblastic leukemia (ALL), Hodgkin lymphoma (HL), mantle cell lymphoma (MCL), myelodysplastic syndromes (MDS), and Waldenstrom macroglobulinemia (WM).  According to the Leukemia and Lymphoma Soc...

Continue reading

Upgrades in Understanding Therapeutic Strategies for Graft-Versus-Host Disease

An educational enduring online activity provided by i3 Health has provided efficiency and knowledge gains encompassing the evolving landscape of therapeutic strategies for graft-versus-host disease (GVHD). Graft-versus-host disease is a complication of allogeneic hematopoietic stem cell transplant (HSCT), affecting between 40% and 60% of patients and accounting for 15% of posttransplant mortality. Acute GVHD is the second-leading cause of transplant-related mortality and typically targets the sk...

Continue reading

Breast Cancer: Genomic and Clinical Risk Predict Outcomes

Women with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer can be provided prognostic information based on clinicopathological features such as tumor size, histologic grade, and the presence of axillary lymph node metastases, but these factors are not always predictive of benefit from adjuvant chemotherapy. Instead, the 21-gene recurrence score, a prognostic predictive tool independent of clinicopathological features, can predict rate of di...

Continue reading